ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

MREO Mereo BioPharma Group PLC

3,11
-0,04 (-1,27%)
02 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Mereo BioPharma Group PLC MREO NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,04 -1,27% 3,11 23:29:41
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,18 3,11 3,24 3,11 3,15
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
03.4.202413:30GLOBEMereo BioPharma to Participate in Fireside Chat at the 23rd..
27.3.202421:01GLOBEMereo BioPharma Reports Full Year 2023 Financial Results and..
05.3.202413:30GLOBEMereo BioPharma to Participate in Fireside Chat at the..
09.2.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202422:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
26.1.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.1.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.1.202422:16EDGAR2Form S-8 - Securities to be offered to employees in employee..
08.1.202413:08EDGAR2Form 8-K - Current report
08.1.202413:00GLOBEMereo BioPharma Provides Update on Pipeline Progress and..
02.1.202422:20EDGAR2Form 3 - Initial statement of beneficial ownership of..
02.1.202422:17EDGAR2Form 3 - Initial statement of beneficial ownership of..
02.1.202422:16EDGAR2Form 3 - Initial statement of beneficial ownership of..
02.1.202422:15EDGAR2Form 3 - Initial statement of beneficial ownership of..
02.1.202422:15EDGAR2Form 3 - Initial statement of beneficial ownership of..
02.1.202422:15EDGAR2Form 3 - Initial statement of beneficial ownership of..
02.1.202422:15EDGAR2Form 3 - Initial statement of beneficial ownership of..
18.12.202322:16EDGAR2Form 8-A12B/A - Registration of securities [Section 12(b)]:..
18.12.202322:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.11.202322:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16.11.202313:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23.10.202322:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23.10.202322:01GLOBEMereo BioPharma Reports on Recent Program Developments and..
17.10.202313:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.10.202322:30GLOBEUltragenyx and Mereo BioPharma Announce Interim Phase 2 Data..
09.10.202314:00GLOBEUltragenyx to Present Setrusumab (UX143) Update at ASBMR..
21.9.202313:00GLOBEMereo BioPharma to Participate in Fireside Chat at the 2023..
20.9.202322:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.9.202313:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.9.202313:30GLOBEMereo BioPharma Reports Interim Financial Results for the..
26.7.202322:31EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06.7.202314:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06.7.202314:00GLOBEUltragenyx Announces First Patients Dosed in Phase 3 Program..
30.6.202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31.5.202313:00GLOBEMereo BioPharma to Present at the Jefferies Healthcare..
23.5.202319:43GLOBEPhase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s..
08.5.202318:46GLOBEMereo BioPharma Regains Compliance with Nasdaq Minimum Bid..
05.5.202322:06GLOBEMereo BioPharma Announces Listing Transfer to Nasdaq Capital..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock